Clinical trials: Thymoma Malignant Recurrent, open to volunteers
Thymoma Malignant Recurrent
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.
- Trial name
- RADIO-RYTHMIC (NCT04731610)
- Testing
- Radiotherapy, Surveillance after resection
- Where
- 21 sites in France
- Volunteers
- 314 people
- Sponsor
- Institut Curie
Thymic Epithelial Tumor, Recurrent Thymoma
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT05104736
- Testing
- PT-112
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Untreated Advanced or Recurrent Thymic Carcinomas
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or…
- Trial name
- Artemis (NCT05832827)
- Testing
- MK-3475, Lenvatinib, Carboplatin
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan